QuickLinks -- Click here to rapidly navigate through this document

Exhibit 99.2

BRISTOL-MYERS SQUIBB COMPANY
SALES
FOR THE PERIOD ENDED SEPTEMBER 30, 2003
($ in millions)

			2003				2002				Percentage Change
Quarter-to-Date			Amount		% of Total		Amount		% of Total		Including Foreign Exchange		Excluding Foreign Exchange
Pharmaceuticals			$	4,389	82.2	%	$	3,687	81.3	%	19	%	15	%
	US Pharmaceuticals			2,714	50.9	%		2,261	49.8	%	20	%	20	%
		Primary Care		1,774	33.3	%		1,344	29.6	%	32	%	32	%
		Oncology/Virology/OTN		940	17.6	%		917	20.2	%	3	%	3	%
	Latin America/Canada			251	4.7	%		219	4.8	%	15	%	14	%
	Europe and Middle East Medicines			1,102	20.6	%		908	20.0	%	21	%	5	%
	Asia/Pacific Medicines			262	4.9	%		240	5.3	%	9	%	5	%
Nutritionals				514	9.7	%		445	9.8	%	16	%	16	%
Other Healthcare				434	8.1	%		405	8.9	%	7	%	3	%
	ConvaTec			221	4.1	%		187	4.1	%	18	%	10	%
	Medical Imaging			130	2.4	%		118	2.6	%	10	%	8	%
	Consumer Medicines			83	1.6	%		100	2.2	%	-17	%	-17	%
Total Company			$	5,337	100.0	%	$	4,537	100.0	%	18	%	14	%

			2003				2002				Percentage Change
Year-to-Date			Amount		% of Total		Amount		% of Total		Including Foreign Exchange		Excluding Foreign Exchange
Pharmaceuticals			$	12,487	82.7	%	$	10,809	81.1	%	16	%	12	%
	US Pharmaceuticals			7,694	51.0	%		6,701	50.3	%	15	%	15	%
		Primary Care		4,811	31.9	%		4,099	30.8	%	17	%	17	%
		Oncology/Virology/OTN		2,883	19.1	%		2,602	19.5	%	11	%	11	%
	Latin America/Canada			715	4.7	%		644	4.8	%	11	%	19	%
	Europe and Middle East Medicines			3,159	20.9	%		2,614	19.6	%	21	%	4	%
	Asia/Pacific Medicines			743	4.9	%		659	4.9	%	13	%	6	%
Nutritionals				1,383	9.2	%		1,365	10.3	%	1	%	2	%
Other Healthcare				1,230	8.1	%		1,151	8.6	%	7	%	2	%
	ConvaTec			602	4.0	%		539	4.0	%	12	%	3	%
	Medical Imaging			378	2.5	%		340	2.6	%	11	%	10	%
	Consumer Medicines			250	1.6	%		272	2.0	%	-8	%	-10	%
Total Company			$	15,100	100.0	%	$	13,325	100.0	%	13	%	9	%

1

BRISTOL-MYERS SQUIBB COMPANY
SEGMENT SALES AND COMPOSITION OF CHANGE IN SALES FOR CONTINUING OPERATIONS
FOR THE PERIOD ENDED SEPTEMBER 30, 2003
(DOLLARS IN MILLIONS)

QUARTER-TO-DATE		Pharmaceuticals			Nutritionals			Convatec			Medical Imaging			Consumer Medicines			Company
Price Increases(Decreases)			1	%		4	%		2	%		2	%		—			1	%
Foreign Exchange			4	%		—			8	%		2	%		—			4	%
Volume			14	%		12	%		8	%		6	%		-17	%		13	%
	Total Change		19	%		16	%		18	%		10	%		-17	%		18	%
Total 2003 Period to Date Sales		$	4,389		$	514		$	221		$	130		$	83		$	5,337
Total 2002 Period to Date Sales		$	3,687		$	445		$	187		$	118		$	100		$	4,537

YEAR-TO-DATE		Pharmaceuticals			Nutritionals			Convatec			Medical Imaging			Consumer Medicines			Company
Price Increases(Decreases)			2	%		-1	%		1	%		5	%		—			2	%
Foreign Exchange			4	%		-1	%		9	%		1	%		2	%		4	%
Volume			10	%		3	%		2	%		5	%		-10	%		7	%
	Total Change		16	%		1	%		12	%		11	%		-8	%		13	%
Total 2003 Period to Date Sales		$	12,487		$	1,383		$	602		$	378		$	250		$	15,100
Total 2002 Period to Date Sales		$	10,809		$	1,365		$	539		$	340		$	272		$	13,325

2

BRISTOL-MYERS SQUIBB COMPANY
2003 THIRD QUARTER REVIEW
($ in Million)

Corporate Overview—Continuing Operations

Revenues:		2003		% of Total		2002		% of Total		% Var.
Pharmaceuticals		$	4,389	82.2	%	$	3,687	81.3	%	19	%
Nutritionals			514	9.7	%		445	9.8	%	16	%
Other Healtcare			434	8.1	%		405	8.9	%	7	%
	ConvaTec		221	4.1	%		187	4.1	%	18	%
	Medical Imaging		130	2.4	%		118	2.6	%	10	%
	Consumer Medicines		83	1.6	%		100	2.2	%	-17	%
			5,337	100.0	%		4,537	100.0	%	18	%

Expenses:				% of Sales					% of Sales		% Var.
COGS		1,908		35.8	%		1,654		36.5	%	15	%
SG&A		1,118		20.9	%		971		21.3	%	15	%
Adv. & Promo.		375		7.0	%		302		6.6	%	24	%
R&D		568		10.7	%		535		11.8	%	6	%
Acquired in-process research & development		—		—			7		0.2	%	-100	%
Provision for restructuring		13		0.2	%		(11	)	-0.2	%	*
Litigation settlement		(4	)	-0.1	%		569		12.5	%	-101	%
Asset impairment charge for ImClone		—		—			379		8.4	%	-100	%
Other (Inc)/Exp		67		1.3	%		16		0.4	%	*
		4,045		75.8	%		4,422		97.5	%	-9	%
Earnings from Continuing Operations Before Minority Interest and IncomeTaxes		1,292		24.2	%		115		2.5	%	*
Provision for income taxes		317					(252	)
Minority interest, net of taxes		91					28
Earnings from Continuing Operations	$	884		16.6	%	$	339		7.5	%	161	%
Earnings Per Share—Basic	$	0.46				$	0.18				156	%
Average Shares—Basic		1,937					1,936
Earnings Per Share—Diluted	$	0.45				$	0.17				165	%
Average Shares—Diluted		1,944					1,941

*

in excess of 200%

Selected Products	Worldwide Sales $ in Millions		% Var.		Change in U.S. Rx Demand 3Q03 vs. 3Q02
Pravachol/Pravigard Pac	$	787	16	%	4	%
Plavix		694	57	%	28	%
Enfamil		209	7	%	N/A
Avapro/Avalide		182	48	%	14	%
Ostomy		133	17	%	N/A
Glucophage XR		103	14	%	-1	%
Sustiva		95	-14	%	18	%
Glucovance		91	44	%	1	%
Wound Care		85	21	%	N/A
Coumadin		67	-19	%	-14	%
Zerit		65	-46	%	-25	%
Videx/Videx EC		57	-15	%	4	%

3

Other (Income)/Expense

	2003		2002
Interest Expense	106		104
Interest Income	(73	)	(39	)
Foreign Exchange	9		(7	)
Other—net	25		(42	)
	67		16

4

BRISTOL-MYERS SQUIBB COMPANY
2003 NINE MONTH REVIEW
($ in Millions)

Corporate Overview—Continuing Operations

Revenues:		2003		% of Total		2002		% of Total		% Var.
Pharmaceuticals		$	12,487	82.7	%	$	10,809	81.1	%	16	%
Nutritionals			1,383	9.2	%		1,365	10.3	%	1	%
Other Healtcare			1,230	8.1	%		1,151	8.6	%	7	%
	ConvaTec		602	4.0	%		539	4.0	%	12	%
	Medical Imaging		378	2.5	%		340	2.6	%	11	%
	Consumer Medicines		250	1.6	%		272	2.0	%	-8	%
			15,100	100.0	%		13,325	100.0	%	13	%

Expenses:				% of Sales					% of Sales		% Var.
COGS		5,389		35.7	%		4,622		34.7	%	17	%
SG&A		3,208		21.1	%		2,820		21.2	%	14	%
Adv. & Promo.		1,157		7.7	%		906		6.8	%	28	%
R&D		1,574		10.4	%		1,564		11.7	%	1	%
Acquired in-process research & development		—		—			167		1.2	%	-100	%
Gain on sale of businesses		—		—			(30	)	-0.2	%	-100	%
Provision for restructuring		8		0.1	%		(10	)	—		-180	%
Litigation settlement		(66	)	-0.4	%		659		4.9	%	-110	%
Asset impairment charge for ImClone		—		—			379		2.8	%	-100	%
Other (Inc)/Exp, net		298		2.0	%		181		1.4	%	65	%
		11,568		76.6	%		11,258		84.5	%	3	%
Earnings from Continuing Operations Before Minority Interest and Income Taxes		3,532		23.4	%		2,067		15.5	%	71	%
Provision for income taxes		859					290
Minority interest, net of taxes		150					117
Earnings from Continuing Operations	$	2,523		16.7	%	$	1,660		12.5	%	52	%
Earnings Per Share—Basic	$	1.30				$	0.86				51	%
Average Shares—Basic		1,936					1,936
Earnings Per Share—Diluted	$	1.30				$	0.85				53	%
Average Shares—Diluted		1,942					1,943

*

in excess of 200%

5

Selected Products	Worldwide Sales $ in Millions		% Var.		Change in U.S. Rx Demand YTD 03 vs. YTD 02
Pravachol/Pravigard Pac	$	2,098	26	%	2	%
Plavix		1,659	25	%	29	%
Avapro/Avalide		527	28	%	14	%
Enfamil		520	-9	%	N/A
Sustiva		405	16	%	19	%
Ostomy		369	11	%	N/A
Glucovance		315	84	%	5	%
Glucophage XR		306	23	%	2	%
Zerit		278	-19	%	-23	%
Coumadin		249	5	%	-14	%
Wound Care		225	13	%	N/A
Videx/Videx EC		199	1	%	3	%

Other (Income)/Expense

	2003		2002
Interest Expense	350		304
Interest Income	(190	)	(80	)
Foreign Exchange	13		4
Other—net	125		(47	)
	298		181

6

BRISTOL-MYERS SQUIBB COMPANY
WORLDWIDE SALES BY PRODUCT
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2003
($ in millions)

			WORLDWIDE						INTERNATIONAL *						DOMESTIC *
			2003		2002		% growth		2003		2002		% growth		2003			2002		% growth
Total Company			$	5,337	$	4,537	18	%	$	2,038	$	1,699	20	%	$	3,299		$	2,838	16	%
PHARMACEUTICALS				4,389		3,687	19	%		1,638		1,399	17	%		2,751			2,288	20	%
Cardiovasculars				1,936		1,531	26	%		656		519	26	%		1,280			1,012	26	%
	Pravachol/Pravigard Pac			787		677	16	%		328		254	29	%		459			423	9	%
	Plavix			694		442	57	%		104		60	73	%		590			382	54	%
	Avapro/ Avalide			182		123	48	%		73		55	33	%		109			68	60	%
	Monopril			120		118	2	%		61		58	5	%		59			60	-2	%
	Coumadin			67		83	-19	%		7		6	17	%		60			77	-22	%
	Capoten/Captopril			49		50	-2	%		49		50	-2	%		—			—	—
Anti-Cancer				1,121		1,003	12	%		309		262	18	%		812			741	10	%
	Oncology Therapeutics Network			574		495	16	%		—		—	—			574			495	16	%
	Paraplatin			245		243	1	%		34		32	6	%		211			211	—
	TAXOL			238		195	22	%		229		187	22	%		9			8	13	%
Anti-Infectives				531		581	-9	%		355		335	6	%		176			246	-28	%
	Sustiva			95		110	-14	%		52		40	30	%		43			70	-39	%
	Zerit			65		120	-46	%		41		50	-18	%		24			70	-66	%
	Cefzil			38		51	-25	%		19		16	19	%		19			35	-46	%
	Videx/ Videx EC			57		67	-15	%		40		35	14	%		17			32	-47	%
	Tequin			45		40	13	%		11		6	83	%		34			34	—
	Maxipime			46		41	12	%		46		41	12	%		—			—	—
	Reyataz			39		—	—			2		—	—			37			—	—
Central Nervous System				69		89	-22	%		40		42	-5	%		29			47	-38	%
	Serzone			32		48	-33	%		1		4	-75	%		31			44	-30	%
	Sinemet			20		29	-31	%		21		20	5	%		(1	)		9	-111	%
	BuSpar			—		10	-100	%		7		7	—			(7	)		3	***
Other Pharmaceuticals
	Glucophage Franchise			236		190	24	%		4		4	—			232			186	25	%
		Glucophage XR		103		90	14	%		—		—	—			103			90	14	%
		Glucovance		91		63	44	%		—		1	-100	%		91			62	47	%
		Glucophage		36		37	-3	%		3		3	—			33			34	-3	%
		Metaglip		6		—	—			1		—	—			5			—	—
	Abilify**			101		—	—			1		—	—			100			—	—
NUTRITIONALS				514		445	16	%		236		215	10	%		278			230	21	%
Infant Formulas				333		290	15	%		107		96	11	%		226			194	16	%
	Enfamil			209		196	7	%		59		56	5	%		150			140	7	%
Other Nutritional Products
	Toddler/Children's Nutritionals			109		98	11	%		109		98	11	%		—			—	—
	Adult Consumer Nutritionals			40		31	29	%		10		10	—			30			21	43	%
OTHER HEALTHCARE				434		405	7	%		195		168	16	%		239			237	1	%
	CONVATEC PRODUCTS			221		187	18	%		148		123	20	%		73			64	14	%
		Ostomy		133		114	17	%		89		78	14	%		44			36	22	%
		Wound Care Products		85		70	21	%		57		44	30	%		28			26	8	%
	MEDICAL IMAGING			130		118	10	%		23		17	35	%		107			101	6	%
		Cardiolite		83		75	11	%		11		7	57	%		72			68	6	%
	CONSUMER MEDICINES			83		100	-17	%		24		28	-14	%		59			72	-18	%

*

This table presents Total Company sales on a legal entity source basis and segment and product sales on a country management reported basis. As a result, the sum of segment sales for International and for Domestic do not tie to the Total Company International and Domestic sales shown above.

**

Includes alliance revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.

***

In excess of 200%

7

BRISTOL-MYERS SQUIBB COMPANY
WORLDWIDE SALES BY PRODUCT
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2003
($ in millions)

			WORLDWIDE						INTERNATIONAL *						DOMESTIC *
			2003		2002		% growth		2003		2002		% growth		2003		2002		% growth
Total Company			$	15,100	$	13,325	13	%	$	5,799	$	4,891	19	%	$	9,301	$	8,434	10	%
PHARMACEUTICALS				12,487		10,809	16	%		4,700		4,007	17	%		7,787		6,802	14	%
Cardiovasculars				5,133		4,262	20	%		1,807		1,468	23	%		3,326		2,794	19	%
	Pravachol/Pravigard Pac			2,098		1,667	26	%		900		694	30	%		1,198		973	23	%
	Plavix			1,659		1,328	25	%		262		173	51	%		1,397		1,155	21	%
	Avapro/ Avalide			527		413	28	%		204		145	41	%		323		268	21	%
	Monopril			352		341	3	%		179		172	4	%		173		169	2	%
	Coumadin			249		238	5	%		18		19	-5	%		231		219	5	%
	Capoten/Captopril			147		157	-6	%		147		156	-6	%		—		1	-100	%
Anti-Cancer				3,243		2,808	15	%		869		732	19	%		2,374		2,076	14	%
	Oncology Therapeutics Network			1,652		1,368	21	%		—		—	—			1,652		1,368	21	%
	Paraplatin			701		576	22	%		95		83	14	%		606		493	23	%
	TAXOL			695		643	8	%		644		519	24	%		51		124	-59	%
Anti-Infectives				1,856		1,762	5	%		1,072		975	10	%		784		787	—
	Sustiva			405		348	16	%		153		118	30	%		252		230	10	%
	Zerit			278		342	-19	%		138		150	-8	%		140		192	-27	%
	Cefzil			210		182	15	%		65		55	18	%		145		127	14	%
	Videx/ Videx EC			199		198	1	%		117		103	14	%		82		95	-14	%
	Tequin			143		140	2	%		28		18	56	%		115		122	-6	%
	Maxipime			133		117	14	%		133		117	14	%		—		—	—
	Reyataz			39		—	—			2		—	—			37		—	—
Central Nervous System				254		349	-27	%		122		123	-1	%		132		226	-42	%
	Serzone			102		185	-45	%		6		15	-60	%		96		170	-44	%
	Sinemet			74		75	-1	%		61		57	7	%		13		18	-28	%
	BuSpar			25		48	-48	%		22		21	5	%		3		27	-89	%
Other Pharmaceuticals
	Glucophage Franchise			723		602	20	%		13		13	—			710		589	21	%
		Glucovance		315		171	84	%		3		2	50	%		312		169	85	%
		Glucophage XR		306		248	23	%		1		1	—			305		247	23	%
		Glucophage		99		183	-46	%		8		10	-20	%		91		173	-47	%
		Metaglip		3		—	—			1		—	—			2		—	—
	Abilify**			203		—	—			2		—	—			201		—	—
NUTRITIONALS				1,383		1,365	1	%		695		639	9	%		688		726	-5	%
Infant Formulas				864		890	-3	%		317		294	8	%		547		596	-8	%
	Enfamil			520		571	-9	%		174		171	2	%		346		400	-14	%
Other Nutritional Products
	Toddler/Children's Nutritionals			313		280	12	%		313		280	12	%		—		—	—
	Adult Consumer Nutritionals			110		99	11	%		32		29	10	%		78		70	11	%
OTHER HEALTHCARE				1,230		1,151	7	%		550		482	14	%		680		669	2	%
CONVATEC PRODUCTS				602		539	12	%		406		347	17	%		196		192	2	%
	Ostomy			369		333	11	%		251		219	15	%		118		114	4	%
	Wound Care Products			225		199	13	%		150		125	20	%		75		74	1	%
MEDICAL IMAGING				378		340	11	%		59		52	13	%		319		288	11	%
	Cardiolite			244		217	12	%		30		24	25	%		214		193	11	%
CONSUMER MEDICINES				250		272	-8	%		85		83	2	%		165		189	-13	%

*

This table presents Total Company sales on a legal entity source basis and segment and product sales on a country management reported basis. As a result, the sum of segment sales for International and for Domestic do not tie to the Total Company International and Domestic sales shown above.

**

Includes alliance revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.

8

BRISTOL-MYERS SQUIBB COMPANY
EARNINGS BEFORE MINORITY INTEREST AND INCOME TAXES
EXCLUDING NON-COMPARABLE ITEMS

		2002
		Q1			Q2		Q3		Q4		TOTAL YEAR
Reported Earnings Before Minority Interest and Income Taxes		$	1,228		$	724	$	115	$	580	$	2,647
Non-comparable items:
	Acquired in-process research and development		160			—		7		2		169
	Provision for restructuring/other		89			4		541		93		727
	Asset impairment charge		—			—		379		—		379
	Gain on sale of businesses/product lines		(30	)		—		—		—		(30	)
	Tax issues		—			—		—		—		—
Earnings Before Minority Interest and Income Taxes excluding non-comparable items		$	1,447		$	728	$	1,042	$	675	$	3,892

		2003
		Q1			Q2			Q3			TOTAL YEAR
Reported Earnings Before Minority Interest and Income Taxes		$	1,075		$	1,165		$	1,292		$	3,532
Non-comparable items:
	Provision for restructuring/other		26			(6	)		55			75
	Litigation settlement		(21	)		(41	)		(4	)		(66	)
Earnings Before Minority Interest and Income Taxes excluding non-comparable items		$	1,080		$	1,118		$	1,343		$	3,541

9

BRISTOL-MYERS SQUIBB COMPANY
DILUTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS
EXCLUDING NON-COMPARABLE ITEMS

		2002
		Q1			Q2		Q3			Q4		TOTAL YEAR *
Reported Diluted EPS		$	0.43		$	0.25	$	0.17		$	0.19	$	1.05
Non-comparable items:
	Acquired in-process research and development		0.05			—		—			—		0.05
	Provision for restructuring/other		0.03			—		0.17			0.03		0.22
	Asset impairment charge		—			—		0.12			—		0.13
	Gain on sale of businesses/product lines		(0.01	)		—		—			—		(0.01	)
	Tax issues		—			—		(0.12	)		—		(0.12	)
Diluted EPS excluding non-comparable items*		$	0.50		$	0.25	$	0.34		$	0.24	$	1.33

		2003
		Q1			Q2			Q3		TOTAL YEAR *
Reported Diluted EPS		$	0.39		$	0.45		$	0.45	$	1.30
Non-comparable items:
	Provision for restructuring/other		0.01			—			0.02		0.03
	Litigation settlement		(0.01	)		(0.01	)		—		(0.02	)
Diluted EPS excluding non-comparable items		$	0.39		$	0.44		$	0.47	$	1.31

*

— amounts may not add due to rounding of individual calculations.

10

BRISTOL-MYERS SQUIBB COMPANY
DEFERRED REVENUE IMPACT ON GROSS SALES
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2003
($ in millions)

	Q1			Q2			Q3		September Year-to-Date
Glucophage	$	32.1		$	25.0		$	23.5	$	80.6
Paraplatin		44.5			—			—		44.5
Serzone		17.2			17.5			7.3		42.0
Plavix		36.8			—			—		36.8
Pravachol		35.3			—			—		35.3
Sustiva		16.2			12.9			—		29.1
Tequin		15.1			11.0			—		26.1
Cefzil		22.0			—			—		22.0
Monopril		20.5			—			—		20.5
Avapro		17.2			—			—		17.2
Videx		7.6			4.2			—		11.8
Glucophage XR		11.3			—			—		11.3
Glucovance		11.0			—			—		11.0
BuSpar		5.4			2.7			0.4		8.5
TAXOL		7.4			—			—		7.4
Zerit		6.8			—			—		6.8
Megace		—			1.0			1.4		2.4
		306.4			74.3			32.6		413.3
Less: Deferred discounts		(10.9	)		(5.0	)		—		(15.9	)
Total Impact on Gross Sales	$	295.5		$	69.3		$	32.6	$	397.4	*

*

amount is further reduced by approximately $86 of sales rebate and return accruals to arrive at an impact on net sales of $311.

11

BRISTOL-MYERS SQUIBB COMPANY
SELECT ADDITIONAL FINANCIAL INFORMATION

	($ in Millions)
Balance Sheet Items	September 30, 2003		December 31, 2002
Cash and cash equivalents	$	4,953	$	3,978
Receivables, net of allowances		3,588		2,968
Short-term borrowings		1,288		1,379
Long-term debt		7,421		6,261
Stockholders' equity	$	10,065	$	8,967

Other Items
Quarterly Dividend (for the three months ended September 30, 2003):	$	.280/share
Gross Margin (for the three months ended September 30, 2003):		64.2	%
Capital Expenditures (for the three months ended September 30, 2003):	$	201 million

12

QuickLinks

BRISTOL-MYERS SQUIBB COMPANY SALES FOR THE PERIOD ENDED SEPTEMBER 30, 2003 ($ in millions)
BRISTOL-MYERS SQUIBB COMPANY SEGMENT SALES AND COMPOSITION OF CHANGE IN SALES FOR CONTINUING OPERATIONS FOR THE PERIOD ENDED SEPTEMBER 30, 2003 (DOLLARS IN MILLIONS)
BRISTOL-MYERS SQUIBB COMPANY 2003 THIRD QUARTER REVIEW ($ in Million)
BRISTOL-MYERS SQUIBB COMPANY 2003 NINE MONTH REVIEW ($ in Millions)
BRISTOL-MYERS SQUIBB COMPANY WORLDWIDE SALES BY PRODUCT FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2003 ($ in millions)
BRISTOL-MYERS SQUIBB COMPANY WORLDWIDE SALES BY PRODUCT FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2003 ($ in millions)
BRISTOL-MYERS SQUIBB COMPANY EARNINGS BEFORE MINORITY INTEREST AND INCOME TAXES EXCLUDING NON-COMPARABLE ITEMS
BRISTOL-MYERS SQUIBB COMPANY DEFERRED REVENUE IMPACT ON GROSS SALES FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2003 ($ in millions)
BRISTOL-MYERS SQUIBB COMPANY SELECT ADDITIONAL FINANCIAL INFORMATION